QurAlis

QurAlis

Edit info

  • Founded: 2016
  • Location: Cambridge, MA
  • Employee range: 11 - 50
  • Clinical stage: Clin1
  • Therapy area: ALS
  • Drug types: NEU
  • Lead product: QRL-201
  • Funding: $88M B Mar 2023; $42M May 2020; $5.5M Seed Nov 2018
  • Investors: EQT Life Sciences, Droia Ventures, Sanofi Ventures, BioInnovation Capital, Viva Biotech Limited, Alexandria, Amgen, MP Healthcare Venture Management, ALS Investment Fund, LS Polaris Innovation Fund, Mission BioCapital, INKEF Capital, Dementia Discovery Fund, Amgen Ventures, MP Healthcare Venture Management, Mitsui Global Investment, Dolby Family Ventures, Mission Bay Capital, Sanford Biosciences


quralis.com

linkedin.com

job board


Business:

ALS cure - Small Molecules, ASO

Drug notes:

QRL-201/QRL-203 Clin0 FTD, Clin0 PLS; QRL-101 Clin1 ALS, Clin0 FTD; QRL-204 Clin0 ALS/FTD, Clin0 FTD

About:

QurAlis is using advances in precision medicine to develop therapeutics for neurodegenerative diseases. Amyotrophic lateral sclerosis (ALS), is a progressive neurodegenerative disease that reduces muscle function and control. By examining the disease-causing genetic alterations linked with ALS, QurAlis is targeting these disease mechanisms using human neuronal stem cell models from ALS patients - this includes the gene that encodes the protein TDP-43. QuAlis has a second platform, FlexASO, a proprietary anti-sense oligonucleotide splice modulator platform to selectively modulate RNA levels to change the expression of genes connected to disease. With these approaches, QurAlis has already established a pipeline of programs in clinical stages.

QurAlis
Director Translational Biomarkers
Cambridge, MA|22 days ago
Apply
QurAlis
Associate Scientist, Compound Management
Cambridge, MA|28 days ago


© 2025 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com